- Home
- KROS
as of 11-28-2025 12:40pm EST
$17.46
$0.04
-0.23%
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 565.0M | IPO Year: | 2020 |
| Target Price: | $22.20 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.12 - $72.37 | Next Earning Date: | 11-05-2025 |
| Revenue: | $246,718,000 | Revenue Growth: | 37798.31% |
| Revenue Growth (this year): | 6657.47% | Revenue Growth (next year): | -95.40% |
AI-Powered KROS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 71.23%
71.23%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Keros Therapeutics Inc. (KROS)
ADAR1 Capital Management, LLC
Sell
10% Owner
KROS Oct 15, 2025
Avg Cost/Share
$17.75
Shares
5,389,264
Total Value
$95,659,436.00
Owned After
0
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | KROS | 10% Owner | Oct 15, 2025 | Sell | $17.75 | 5,389,264 | $95,659,436.00 | 0 |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
Zacks
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
📊
AI Sentiment
Positive
7/10
Compare KROS vs Leading Stocks
See how KROS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.